Cancer Genetics postpones $18 million IPO

By
A A A

Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, postponed its IPO on Tuesday, citing poor market conditions. The Rutherford, NJ-based company was founded in 1999 and booked $4 million in sales for the year ended 12/31/2012. Aegis Capital was set to be the sole bookrunner on the deal.

This was the diagnostics company's third postponement. Cancer Genetics previously attempted to price in May 2012 ($48 million deal size) and February 2013 ($35 million deal size).



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CGIX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,376
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com